17.01.2015 Views

LibraryPirate

LibraryPirate

LibraryPirate

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

, A - a, and B - b are all greater than or equal to 5. Alternatively, when sample sizes<br />

are sufficiently large, we may test the null hypothesis by means of the chi-square test.<br />

Further Reading The Fisher exact test has been the subject of some controversy<br />

among statisticians. Some feel that the assumption of fixed marginal totals is unrealistic<br />

in most practical applications. The controversy then centers around whether the test is<br />

appropriate when both marginal totals are not fixed. For further discussion of this and<br />

other points, see the articles by Barnard (13, 14, 15), Fisher (16), and Pearson (17).<br />

Sweetland (18) compared the results of using the chi-square test with those obtained<br />

using the Fisher exact test for samples of size A + B = 3 to A + B = 69. He found close<br />

agreement when A and B were close in size and the test was one-sided.<br />

Carr (19) presents an extension of the Fisher exact test to more than two samples<br />

of equal size and gives an example to demonstrate the calculations. Neave (20) presents<br />

the Fisher exact test in a new format; the test is treated as one of independence rather<br />

than of homogeneity. He has prepared extensive tables for use with his approach.<br />

The sensitivity of Fisher’s exact test to minor perturbations in 2 * 2 contingency<br />

tables is discussed by Dupont (21).<br />

EXAMPLE 12.6.1<br />

12.6 THE FISHER EXACT TEST 631<br />

The purpose of a study by Justesen et al. (A-12) was to evaluate the long-term efficacy<br />

of taking indinavir/ritonavir twice a day in combination with two nucleoside reverse transcriptase<br />

inhibitors among HIV-positive subjects who were divided into two groups.<br />

Group 1 consisted of patients who had no history of taking protease inhibitors (PI Naïve).<br />

Group 2 consisted of patients who had a previous history taking a protease inhibitor (PI<br />

Experienced). Table 12.6.2 shows whether these subjects remained on the regimen for<br />

the 120 weeks of follow-up. We wish to know if we may conclude that patients classified<br />

as group 1 have a lower probability than subjects in group 2 of remaining on the<br />

regimen for 120 weeks.<br />

TABLE 12.6.2 Regimen Status at 120 Weeks<br />

for PI Naïve and PI Experienced Subjects Taking<br />

Indinavir/ Ritonavir as Described in Example 12.6.1<br />

Remained in<br />

the Regimen<br />

for 120 Weeks<br />

Total Yes No<br />

1 (PI Naïve) 9 2 7<br />

2 (PA Experienced) 12 8 4<br />

Total 21 10 11<br />

Source: U.S. Justesen, A. M. Lervfing, A. Thomsen, J. A. Lindberg,<br />

C. Pedersen, and P. Tauris, “Low-Dose Indinavir in Combination<br />

with Low-Dose Ritonavir: Steady-State Pharmacokinetics and<br />

Long-Term Clinical Outcome Follow-Up,” HIV Medicine, 4 (2003),<br />

250–254.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!